Caregivers Day

In English
Caregivers Day, as part of ISFTD2024, will be held for family members and professional caregivers on Saturday, 21 September, 2024.

The registration fee for attending Caregivers Day only is EUR 50.

A full congress registration is required if you are also planning to attend the ISFTD 2024 congress on the other days. During registration for the congress, you can indicate that you will be attending the Caregivers Day.

 

In het Nederlands
Caregivers Day, als onderdeel van ISFTD2024, wordt gehouden voor familieleden en professionele zorgverleners op zaterdag 21 september 2024.

Het inschrijfgeld voor het bijwonen van alleen Caregivers Day is EUR 50.

Een volledige congresregistratie is vereist als u ook van plan bent het ISFTD 2024 congres op de andere dagen bij te wonen. Tijdens de registratie voor het congres kunt u aangeven dat u Caregivers Day bijwoont.

 

Programme overview

In English
Dutch/English translation will be offered for the sessions in the morning and for parallel session 3 in the afternoon.
Parallel sessions 1 + 2 in the afternoon will only be offered in Dutch.

The plenary sessions will take place in the Emerald Room.

In het Nederlands
Nederlands/Engelse vertaling zal worden aangeboden voor de ochtendsessies en voor parallelsessie 3 in de middag. Parallelsessies 1 en 2 in de middag zullen alleen in het Nederlands worden aangeboden.

De plenaire sessies zullen plaatsvinden in de Emerald Room

Understanding Familial FTD and Charting Your Path

Time: 15:40 - 16:15

Inzicht in Familiale FTD en Uw Pad Uitzetten

Room G109

Dutch/English translation will be offered  /  Nederlands/Engelse vertaling zal worden aangeboden 

ISTAART PIA – Carmela Tartaglia, Canada

Time: 12:25 - 12:30

FTD Disorders Registry – Susan Dickinson, USA

Time: 12:20 - 12:25

ALLFTD – Adam Boxer, USA, Bradley Boeve, USA & Howie Rosen, USA

Time: 12:05 - 12:20

NIC-FTD – Simon Ducharme, Canada

Time: 11:50 - 12:05

INCLUSE – Boon Lead Tee, USA & Maria Luisa Gorno Tempini, USA

Time: 11:35 - 11:50

GENFI – Jonathan Rohrer, UK

Time: 11:20 - 11:35

Session 14: Consortia presentation

Time: 11:20 - 12:30

Transition moment

Time: 16:15 - 16:20

Wisselmoment

Workshop Alzheimer Nederland / Discussion group

Time: 14:10 - 14:40

Workshop Alzheimer Nederland /Gespreksgroep – Room G109 Dutch/English translation will be offered  /  Nederlands/Engelse vertaling zal worden aangeboden 

Live peer support group – Alzheimer Nederland

Time: 13:30 - 14:40

Live lotgenotengroep – Alzheimer Nederland – Room G109

Exploring quality of life impact reported by caregivers in the FTD Insights Survey

Time: 12:15 - 12:25

Onderzoek naar de impact op de kwaliteit van leven gerapporteerd door mantelzorgers in de FTD Insights-enquête

Papa!

Time: 11:55 - 12:15

When Life Defies illness: fighting FTD day by day

Time: 10:42 - 10:52

Wanneer het leven de ziekte tart: Dag na dag vechten tegen FTD

Photo competition awards ceremony / Prijsuitreiking fotowedstrijd

Time: 11:12 - 11:17

PB10.3: The Hinting Task–Dutch version Differentiates Patients with Frontotemporal Dementia and Alzheimer’s Disease Dementia from Controls

Time: 14:53 - 14:57

PB10.2: Different grey matter, white matter and functional connectivity involvement in genetic FTD: a cross-modality GENFI study

Time: 14:49 - 14:53

PB10.1 Genetic Association between ANXA11 and FTLD-TDP Type C

Time: 14:45 - 14:49

O10.6 Heteromeric amyloid filaments of annexin A11 and TDP-43 in FTLD-TDP Type C

Time: 14:35 - 14:45

Transition moment

Time: 15:35 - 15:40

Wisselmoment

Transition moment

Time: 14:05 - 14:10

Wisselmoment

AFTD program of choice

Time: 15:40 - 16:15

AFTD- programma naar
keuze – Room G109

Dutch/English translation will be offered  / Nederlands/Engelse vertaling zal worden aangeboden

Questions / discussion with speakers

Time: 11:17 - 11:30

Vragen / discussie met bovenstaande sprekers

ISFTD EMCR announcement

Time: 10:55 - 11:00

Marco Blom, manager Wetenschappelijk onderzoek en adjunct-directeur, Alzheimer Nederland

Time: 16:20 - 16:40

Room G106

Connections for Care: Community Advocacy and Support at Every Stage of Life with FTD

Time: 15:00 - 15:35

Verbindingen voor zorg: Belangenbehartiging en ondersteuning van de gemeenschap in elke fase van het leven met FTD

 

Room G109

Dutch/English translation will be offered  /  Nederlands/Engelse vertaling zal worden aangeboden 

Biopharma perspective

Time: 17:10 - 17:20

O10.7: TBD

Time: 15:00 - 15:15

O10.5: FOXY – A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia

Time: 14:25 - 14:35

O10.5: TBD

Time: 14:30 - 14:45

O10.4: MRI-based frontotemporal dementia subtyping using multi-type parallel feature embedding and fusion

Time: 14:15 - 14:25

O10.3: Tau accumulation disrupts the TDP-43 interactome and function.

Time: 14:00 - 14:15

O10.2: Massively multiplexed immunofluorescence provides new insights into FTD/ALS

Time: 13:45 - 14:00

Non-profit perspective, including the dearth of available participants for active trials, and high-level of known barriers

Time: 17:20 - 17:30

O03.3: An international COS-PPA; a consensus study to identify a core outcome set for PPA

Time: 16:50 - 17:00

O03.2: The Multidomain impairment rating (MIR) Scale: Comparison to the CDR+NACC FTLD in the ALLFTD consortium

Time: 16:40 - 16:50

O03.1: Platform trials for FTD and PSP

Time: 16:30 - 16:40

Q&A session 01.2 Diversity & Epidemiology

Time: 12:45 - 12:50

Q&A session 01.1: Diversity & Epidemiology

Time: 11:42 - 11:45

test

Time: 00:00 - 00:00

TBA

Time: 12:00 - 12:20

Volgt

How can patient advocacy groups and politicians work together

Time: 13:30 - 13:50

TBA

Time: 14:10 - 14:40

Volgt

PB7.5: Practice effects are reduced within prodromal and symptomatic FTD mutation carriers using the Ignite app

Time: 11:16 - 11:20

PB7.2: Transcranial Direct Current Stimulation for Primary Progressive Aphasia: Individualised Targeting Using Neuroimaging

Time: 11:04 - 11:08

PB7.4: The dynamics of auditory working memory impairment in primary progressive aphasia and Alzheimer’s disease

Time: 11:12 - 11:16

PB7.3: Spontaneous speech alterations and evolution in primary progressive aphasia variants 

Time: 11:08 - 11:12

PB7.1: The Empathy Effect: Improving FTD Support, Medical Practices and Societal Awareness with an Immersive Approach

Time: 11:00 - 11:04

O13.8: TBD

Time: 10:15 - 10:30

O08.1: Glymphatic dysfunction occurs across clinical phenotypes of motor neuron disease

Time: 17:30 - 17:45

O13.5: Blood-based inflammation markers relate to neuroinflammation and survival in syndromes associated with frontotemporal lobar degeneration

Time: 09:30 - 09:45

O13.4: Ultra-high resolution T2*-weighted ex vivo 7T MRI laminar patterns of pathology in FTLD

Time: 09:15 - 09:30

O13.3: Carboxy-terminal blockade of sortilin binding enhances progranulin gene therapy, a potential treatment for FTD

Time: 09:00 - 09:15

O13.2: New insights into aFTLD-U through the brain transcriptomics analysis

Time: 08:45 - 09:00

O13.1: Discovery of Novel Splicing Alterations in FTLD-TDP: Insights from Brain transcriptomics Using Short-and Long-read sequencing

Time: 08:30 - 08:45

O06.5: RNA-binding protein misloclization in FTLD and ALS

Time: 12:00 - 12:15

O06.4: Neuroinflammation and protein aggregation and its relationship to cognitive decline in FTD

Time: 11:45 - 12:00

O06.2: Neuropathology-based approaches reveal novel pathogenic aspects of progressive supranuclear palsy

Time: 11:15 - 11:30

O06.1: Annexin A11 proteinopathy in ANXA11 variant cases and FTLD-TDP Type C

Time: 11:00 - 11:15

O10.1: Identification of a major genetic risk factor for aFTLD-U

Time: 13:30 - 13:45

PB4.4: White matter Hyperintensities are an early biomarker in GRN-related FTD

Time: 11:57 - 12:00

PB4.3: Genetic influences on progression of clinical, motor, fluid biomarker and MRI changes in familial FTLD

Time: 11:53 - 11:57

PB4.2: UNC13A polymorphism shortens survival in behavioural variant frontotemporal dementia

Time: 11:49 - 11:53

PB4.1: Integrative transcriptomic analysis of the frontal cortex reveals an upregulation of S100A6 in FTLD-TDP

Time: 11:45 - 11:49

O09.6: TMEM106B loss-of-function impairs the presynaptic protein machinery in human iPSC-derived cortical neurons

Time: 11:30 - 11:45

O09.5: C9orf72 repeat expansion affects immune response in a xenografted microglia mouse model

Time: 11:15 - 11:30

O09.4: AlphaFold2 Modeling of MAPT mutation-derived Tau conformations Plus biochemical data support TauC3’s involvement in FTLD-Tau

Time: 11:00 - 11:15

O09.3: TDP-43 monomerization drives early pathological changes in FTD 

Time: 10:00 - 10:15

O09.2: Regulation of tau phosphorylation, secretion and splicing by variations in temperature during the sleep-wake cycle

Time: 09:45 - 10:00

Cross links between FTD and MND

Time: 15:45 - 16:15

The history of FTD

Time: 10:30 - 11:00

O09.1: Synaptic dysfunction in FTD patient-derived iPSC-neurons

Time: 09:30 - 09:45
Annakaisa Haapasalo, Finland

O08.5: Unbiased CSF proteomics reveals genotype-specific signatures of presymptomatic and symptomatic familial frontotemporal lobar degeneration

Time: 18:15 - 18:30

O08.4: Early dysregulation of microglia-secreted AIM in frontotemporal dementia caused by CHMP2B mutation

Time: 18:15 - 18:30

O08.3: CSF TMEM106B as a fluid biomarker in familial and sporadic frontotemporal lobar degeneration

Time: 18:00 - 18:15

O08.2: Clinical Performance of Plasma Aβ1-42/Aβ1-40, p-tau217 and Neurofilament Light in Sporadic Frontotemporal Dementia Spectrum Disorders

Time: 17:45 - 18:00

O13.7: Detection of TDP-43 seeding activity in the olfactory mucosa from patients with Frontotemporal Dementia

Time: 10:00 - 10:15

PB3.4: Psychoeducational program in Primary Progressive Aphasia: An innovative collaboration between the community and academic environments

Time: 15:57 - 16:31

PB3.3: The Position of Sporadic FTD Cases within the Human Proteomics Neurodegenerative Disease Landscape

Time: 15:53 - 15:57

PB3.2: The identification of GRN mutation carriers by a simple finger stick collection – DropAD

Time: 15:49 - 15:53

PB3.1: CSF/serum albumin ratio in frontotemporal lobar degeneration syndromes

Time: 15:45 - 15:49

O07.5: Memory in behavioural-variant frontotemporal dementia: comparison with normative data and amnestic and non-amnestic Alzheimer’s disease

Time: 15:30 - 15:45

O07.3: Criminal minds in dementia: A systematic review & quantitative meta-analysis

Time: 15:00 - 15:15

O07.2: The Signature Initiative 2 years later: towards the clinical recommendations for socio-cognitive assessment in neurocognitive disorders

Time: 14:45 - 15:00

O07.1: Exploring Emotion and emotional variability as digital biomarkers in Frontotemporal dementia speech

Time: 14:30 - 14:45

PB6.4: Detection of misfolded TDP-43 in CSF from genetic FTD and FTD/ALS patients

Time: 17:38 - 17:42

PB6.3: Progranulin deficiency in microglia and its impact in neurodegeneration

Time: 17:34 - 17:38

PB6.2: Increased levels of TMEM106B lead to lysosomal dysfunction and aberrant neurotrophin signaling in mice

Time: 17:34 - 17:38

PB6.1: Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes

Time: 17:30 - 17:34

O12.2: Utility of case review meetings in Japanese FTD consortium FTLD-J

Time: 17:15 - 17:30

O12.1: Towards improved knowledge of the phenotypes associated with C9orf72 repeat expansion – A multicenter cohort study

Time: 17:00 - 17:15

PB5.4: Behavioural variant frontotemporal dementia and Alzheimer’s disease differ in favourite music activation profiles on fMRI

Time: 16:57 - 17:00

PB5.3: Neuropsychiatric shadows: Unraveling the deeper ties of psychotic symptoms in bvFTD

Time: 16:53 - 16:57

PB5.2: Paying attention – what hallucinations reveal about FTD

Time: 16:49 - 16:53

PB5.1: Connectomic markers of executive function in FTLD and typical aging

Time: 16:45 - 16:49

O11.2: Differential diagnosis of motor speech disorders in FTD; a case-based tutorial

Time: 16:30 - 16:45

O11.1: Longitudinal behavioral and neuropsychiatric changes in genetic frontotemporal dementia: from presymptomatic to symptomatic conversion

Time: 16:15 - 16:30

PB2.4: Onset-predictive biomarker testing for clinical trial recruitment in FTD: perspectives of (potential) mutation carriers

Time: 09:42 - 09:45

PB2.3: Interim Safety and Biomarker Data From upliFT-D Trial of PBFT02 in FTD with GRN Mutations

Time: 09:38 - 09:42

PB2.2: Communication Bridge 2: Results from a global randomized controlled trial (RCT) for primary progressive aphasia

Time: 09:34 - 09:38

PB2.1: Baseline characteristics for INFRONT-3: A Phase 3 double-blind, placebo-controlled 96-week study evaluating latozinemab in FTD-GRN

Time: 09:30 - 09:34

O05.2: Differentiating sporadic bvFTD from late-onset PPD: the DIPPA-FTD study

Time: 09:15 - 09:30

O05.1: Disentangling Behavioral Problems in Dementia Subtypes: From Fixed Interests to Empathy Deficits

Time: 09:00 - 09:15

PB1.4: The influence of cultural background on social cognition in genetic FTD

Time: 12:35 - 12:45

O04.4: Deciphering Distinct Genetic Risk factors for FTLD-TDP subtypes via whole genome sequencing

Time: 18:45 - 19:00

O04.3: Investigation of genetic modifiers in the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Study

Time: 18:30 - 18:45

O04.2: Understanding the role of somatic mutations in TARDBP in FTLD-TDP type C

Time: 18:15 - 18:30

O01.8: Sex differences in clinical phenotypes of behavioural variant frontotemporal dementia

Time: 12:25 - 12:35

O01.7: Influence of Biological Sex on Cognitive Resilience in Genetic FTLD

Time: 12:15 - 12:25

O01.6: Frontotemporal Dementia in India – Perspective and unique insights

Time: 12:05 - 12:15

O01.5: Predictors of survival in syndromes associated with Frontotemporal Lobar Degeneration: a European registry

Time: 11:55 - 12:05

O01.4: Neurodevelopmental trajectories towards neurodegenerative disease

Time: 11:45 - 11:55

PB1.3: Insights into Dyslexia Phenotypes and Hypometabolism in Spanish-Speaking Patients with Primary Progressive Aphasia

Time: 11:38 - 11:45

PB1.2: The role of bilingualism on functional decline and neurodegeneration in distinct ADRD neuropathologies

Time: 11:34 - 11:38

PB1.1: Cross-Linguistic Assessment Of Oral Production In Primary Progressive Aphasia: Insight From English, Chinese, and Italian

Time: 11:30 - 11:34

O01.3: Navigating dysgraphia phenotypes in Chinese lvPPA: A clinical and imaging analysis

Time: 11:20 - 11:30

O02.5: Individualized atrophy-based prediction of dementia progression in familial FTLD with Bayesian LME modeling

Time: 15:00 - 15:15

O02.4: Validating 11C-PK11195 PET in pathologically heterogeneous FTD

Time: 14:45 - 15:00

O02.3: Altered spatiotemporal dynamics of interoception associated with social cognition impairment in bvFTD

Time: 14:30 - 14:45

O02.2 Mapping the staging of neuroimaging trajectories in FTD: new insights using voxel-based analysis

Time: 14:15 - 14:30

Session 04 – Genetics

Time: 17:30 - 18:30

Session 03 – Clinical trials and Management

Time: 16:00 - 17:30

Chair: Shelley Forrest

O02.1: Uncovering distinct trajectories of brain atrophy and tau deposition in PSP

Time: 14:00 - 14:15

O01.2: Brain imaging profiles of apraxia of speech and agrammatism in Japanese and English speakers diagnosed with nonfluent variant primary progressive aphasia

Time: 11:10 - 11:20

O01.1: A cross-linguistic review of the quantitative markers of speech and language of the FTD Spectrum

Time: 11:00 - 11:10

O04.1: Multi-transcriptomic analyses reveal altered expression profiles in Pick’s disease parietal tissue

Time: 18:00 - 18:15

Panel discussion

Time: 17:00 - 17:30

Clinical trials and management / Trial design

Closing with drinks

Time: 16:40 - 17:30

Afsluiting met drankje

Palliative care

Time: 15:40 - 16:15

Palliatieve zorg – Room G107

Management of behavioural symptoms in FTD

Time: 15:40 - 16:15

Omgaan met probleemgedrag bij FTD –  Room G106

Management of mourning

Time: 15:00 - 15:35

Omgaan met levende rouw – Room G107

Language variants

Time: 15:00 - 15:35

Taalvarianten – Room G106

Break

Time: 14:40 - 15:00

Pauze

Legal aspects

Time: 14:10 - 14:40

Juridische aspecten – Room G107

Music therapy

Time: 14:10 - 14:40

Muziek therapie – Room G106

Management of behavioural symptoms in FTD

Time: 13:30 - 13:50

Omgaan met probleemgedrag bij FTD – Room G107

Genetic FTD

Time: 13:30 - 13:50

Erfelijke FTD – Room G106

Information national young onset dementia cohort

Time: 12:25 - 12:35

Informatie landelijk dementie op jonge leeftijd cohort

Poster sessions

Time: 12:35 - 13:30

Poster sessies

LUNCH with info stands

Time: 12:35 - 13:30

LUNCH met info stands

Interview with caregiver

Time: 12:00 - 12:20

Interview met naaste

From a caregiver perspective

Time: 11:20 - 11:40

FTD vanuit mantelzorg perspectief

Break

Time: 11:30 - 11:55

Pauze

Medication development and trials

Time: 10:22 - 10:42

Medicatie-ontwikkeling en trials

Challenges in non-genetic FTD

Time: 10:52 - 11:12

Uitdagingen bij niet erfelijke FTD (diagnose)

FTD and related disorders: an overview and recent developments

Time: 09:55 - 10:22

FTD en gerelateerde ziekten: een overzicht en recente ontwikkelingen

 

Welcome, registration, coffee

Time: 09:00 - 09:30

Inloop – inschrijven – koffie

Plenary session 4: Clinical Case discussions

Time: 08:30 - 09:00

Closing ceremony

Time: 12:30 - 13:00

Oral presentations

Time: 11:15 - 12:30

consortia presentation

Speech of the President of the ISFTD

Time: 13:45 - 14:00

Presentation of the next venue (ISFTD2026)

Time: 13:30 - 13:45

Panel discussion

Time: 16:45 - 17:30

Communication on FTD: how to deal with the stigma and how to generate awareness

Plenary session

Time: 14:00 - 14:30

Cross cultural aspects of cognition in FTD

Opening act

Time: 10:00 - 10:30

Plenary session

Time: 11:00 - 11:30

Gala dinner

Time: 19:00 - 23:00

Speech of the President of the ISFTD

Time: 06:31 - 06:31

Presentation of the next venue

Time: 06:31 - 06:31

Opening, Welcome reception & Speech of the President

Time: 19:30 - 21:00

Poster Blitz sessions

Time: 11:00 - 11:15

Poster Blitz sessions

Time: 11:30 - 11:45

Poster Blitz sessions

Time: 11:30 - 11:45

Poster Blitz sessions

Time: 12:15 - 12:30

Oral presentations

Time: 08:30 - 10:30

Oral presentations

Time: 17:15 - 18:30

Oral presentations

Time: 14:00 - 16:00

Oral presentations

Time: 08:30 - 10:30

Oral presentations

Time: 17:00 - 18:45

Oral presentations

Time: 14:00 - 15:30

Oral presentations

Time: 09:45 - 11:00

Break

Time: 16:00 - 16:45

Break

Time: 10:30 - 11:00

Break

Time: 10:30 - 11:00

Break

Time: 15:30 - 16:00

Break

Time: 11:00 - 11:30

FTD in a dish / New models in FTD

Time: 16:00 - 16:30

Oral presentations

Time: 13:45 - 15:00

Oral presentations

Time: 17:30 - 18:30

Oral presentations

Time: 11:00 - 12:15

FTD from bench to bedside

Time: 08:00 - 08:30

Plenary session

Time: 10:30 - 11:00

FTLD pathology and copathology

Plenary session 7: TDP pathophysiology

Time: 09:00 - 09:30

Plenary session

Time: 06:31 - 06:31

Plenary session 3: A functional network approach to FTD

Time: 08:00 - 08:30

Lunch

Time: 13:00 - 14:00

Lunch break, Poster viewing, visiting exhibition

Time: 11:45 - 13:30

Lunch break, Poster viewing, visiting exhibition

Time: 11:45 - 13:30

Lunch break, Poster viewing, visiting exhibition

Time: 12:30 - 13:30

Plenary session

Time: 10:30 - 11:00

The history of FTD

Break

Time: 15:00 - 15:30

Registration open

Time: 08:30 - 10:00